🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 92765F108 (prev. 867328700 )
- Market Cap
- Micro Cap · $51 Million
- IPO
- 10/1/2010 · $.35/unit
- Previous Symbol
- SNSS (changed 2/24/2021)
- Previous Name
- Sunesis Pharmaceuticals, Inc.
Business: Viracta Therapeutics, Inc. is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas
Notes: Feb. 24, 2021 -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021. <p> September 8, 2016 -- Sunesis Pharmaceuticals, Inc. (SNSS) will effect a one-for-six (1-6) reverse split of its common stock. The CUSIP number will change to 867328700.
Company Contact
- CEO
- Parvinder S. Hyare
- CFO
- Tina Gullotta
- Headquarters
- 2533 S. Coast Hwy. 101, Suite 210, Cardiff, CA 92007
- Phone
- 858-400-8470
- Fax
- 650-266-3501
- Investor Relations
- Par Hyare · 650-266-3784 · info@sunesis.com